Dementia is arguably the greatest single global healthcare challenge, affecting more than 47 million people worldwide at an estimated annual cost to the global economy of over £638 billion. Despite the increasing scale of the problem, research has not produced any disease-modifying treatments, with current therapies limited to symptomatic treatments having no effect on underlying disease.
The Dementia Discovery Fund (“DDF”), who recently raised £250 million, is a highly innovative new fund backed by the UK Government, Alzheimer’s Research UK and seven of the world’s leading pharmaceutical and biotech companies. The DDF is funding the discovery and development of new disease-modifying treatments for Alzheimer’s and other forms of dementia with the intent to improve dramatically the quality of life for the growing number of dementia sufferers and their families while also generating a financial return.
Laurence Barker, Chief Business Officer, and Barbara Tate, Venture Partner, will be in attendance to present an overview of the DDF, key areas of interest and investment models. Following the presentation, they will be on hand to meet with a handful of approved applicants one-on-one after the presentation. To be considered for a one-on-one meeting, please complete a short application through the link below.
10:30 | Registration Opens and Networking
11:00 | Presentation and Q&A
11:45 | Networking Lunch
13:00 | One-on-one Meetings
15:30 | Close
One-on-one meetings are free, but companies must apply to participate (deadline: 24th October):
• One-on-one-meetings London: jlabs.tv/DDfLondon
• One-on-one-meetings Cambridge: jlabs.tv/DDfCambridge
- BARBARA TATE PhD, Venture Partner, Dementia Discovery Fund
- LAURENCE BARKER, Chief Business Officer, Dementia Discovery Fund
OHT complimentary code: PartnerGuest.